Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.58 |
| ▸ | CASP1 | P29466 | 9/20 | 0.56 |
| ▸ | CTSL | P07711 | 2/20 | 0.56 |
| ▸ | CTSS | P25774 | 2/20 | 0.56 |
| ▸ | CTSK | P43235 | 3/20 | 0.56 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.55 |
| ▸ | ELANE | P08246 | 1/20 | 0.54 |
| ▸ | CASP3 | P42574 | 1/20 | 0.53 |
| ▸ | CTSB | P07858 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5194569 | 1.00 | ATM (0.58) | ATMCASP1CTSLCTSSCTSK | |
| SCHEMBL265847 | 1.00 | ATM (0.58) | ATMCASP1CTSLCTSSCTSK | |
| SCHEMBL26088808 | 0.90 | ATM (0.54) | ATMCASP1CTSLCTSSCTSK | |
| SCHEMBL22321304 | 0.90 | ATM (0.54) | ATMCASP1CTSLCTSSCTSK | |
| SCHEMBL22321302 | 0.90 | ATM (0.54) | ATMCASP1CTSLCTSSCTSK | |
| SCHEMBL6841182 | 0.88 | ATM (0.56) | ATMCASP1CTSLCTSSCTSK | |
| SCHEMBL8972716 | 0.88 | ATM (0.56) | ATMCASP1CTSLCTSSCTSK | |
| SCHEMBL4173427 | 0.88 | ATM (0.56) | ATMCTSLCTSSCTSKCTRB1 | |
| SCHEMBL6841162 | 0.88 | ATM (0.56) | ATMCTSLCTSSCTSKCTRB1 | |
| SCHEMBL10559163 | 0.87 | ATM (0.54) | ATMCTSLCTSSCTSKCTRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 106 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115716856-A | Method for synthesizing aminoglycoside antibiotic arbekacin | 山东厚德精诚药业有限公司 | 2023-02-28 | — | — | CN | claimed |
| US-12552767-B2 | 3-heteroaryl pyrrolidine and piperidine orexin receptor agonists | MERCK SHARP & DOHME LLC (US) | 2026-02-17 | — | — | US | disclosed |
| EP-3924058-B1 | 5-ALKYL PYRROLIDINE OREXIN RECEPTOR AGONISTS | MERCK SHARP & DOHME LLC (US) | 2026-01-07 | — | — | EP | disclosed |
| US-12312332-B2 | Heteroaryl pyrrolidine and piperidine orexin receptor agonists | MERCK SHARP & DOHME LLC (US) | 2025-05-27 | — | — | US | disclosed |
| EP-4010314-B1 | HETEROARYL PYRROLIDINE AND PIPERIDINE OREXIN RECEPTOR AGONISTS | MERCK SHARP & DOHME LLC (US) | 2024-02-28 | — | — | EP | disclosed |
| US-20240002359-A1 | 3-HETEROARYL PYRROLIDINE AND PIPERIDINE OREXIN RECEPTOR AGONISTS | MERCK SHARP & DOHME LLC (US) | 2024-01-04 | — | — | US | disclosed |
| US-20240002397-A1 | 3-AMINO PYRROLIDINE AND PIPERIDINE MACROCYCLIC OREXIN RECEPTOR AGONISTS | MERCK SHARP & DOHME LLC (US) | 2024-01-04 | — | — | US | disclosed |
| US-20230365533-A1 | BICYCLOHEPTANE PYRROLIDINE OREXIN RECEPTOR AGONISTS | MERCK SHARP & DOHME LLC (US) | 2023-11-16 | — | — | US | disclosed |
| EP-4255429-A1 | 3-HETEROARYL PYRROLIDINE AND PIPERIDINE OREXIN RECEPTOR AGONISTS | Merck Sharp & Dohme LLC (US) | 2023-10-11 | — | — | EP | disclosed |
| EP-4247801-A1 | 3-AMINO PYRROLIDINE AND PIPERIDINE MACROCYCLIC OREXIN RECEPTOR AGONISTS | Merck Sharp & Dohme LLC (US) | 2023-09-27 | — | — | EP | disclosed |
| US-20050272669-A1 | Pyrazole derivatives, medicinal composition containing the same, medicinal use thereof, and intermediate for production thereof | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2005-12-08 | — | — | US | disclosed |
| EP-1548024-A1 | PYRAZOLE DERIVATIVES, MEDICINAL COMPOSITION CONTAINING THE SAME, MEDICINAL USE THEREOF, AND INTERMEDIATE FOR PRODUCTION THEREOF | Kissei Pharmaceutical Co., Ltd. (JP) | 2005-06-29 | — | — | EP | disclosed |
| CN-1484645-A | Novel beta-lactam compound and process for producing the same | ס����ҩ��ʽ���� | 2004-03-24 | — | — | CN | disclosed |
| CN-1355811-A | Integrain receptor antagaonists | BASF AG (DE) | 2002-06-26 | — | — | CN | disclosed |
| US-6075051-A | INDUCING LOCAL AND SYSTEMIC RESISTANCE OF THE CROP BY APPLYING TO THE CROP OR ITS LOCUS A COMPOSITION CONTAINING AN EFFECTIVE AMOUNT OF AT LEAST ONE BETA-AMINOBUTYRIC ACID OR BETA-AMINO VALERIC ACID AND SALTS THEREOF | AGROGENE LTD. (IL) | 2000-06-13 | — | — | US | disclosed |
| EP-0883613-A1 | SULFONAMIDE DERIVATIVES AS 5HT7 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1998-12-16 | — | — | EP | disclosed |
| US-5830919-A | APPLYING AN AMINOBUTYRIC ACID COMPOUND | AGROGENE LTD. (IL) | 1998-11-03 | — | — | US | disclosed |
| WO-1997029097-A1 | SULFONAMIDE DERIVATIVES AS 5HT7 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1997-08-14 | — | — | WO | disclosed |
| EP-0736037-A1 | NOVEL INTERMEDIATES FOR THE SYNTHESIS OF L-ASPARTYL-D-$g(a)-AMINOALKANOYL-(S)-N-$g(a)-ALKYLBENZYL AMIDES USEFUL AS ARTIFICIAL SWEETENERS | THE COCA-COLA COMPANY (US) | 1996-10-09 | — | — | EP | disclosed |
| US-5518903-A | HYDROLYSIS OF ESTER | CHISSO CORPORATION (JP) | 1996-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230365533-A1 | BICYCLOHEPTANE PYRROLIDINE OREXIN RECEPTOR AGONISTS | HCRTR1, HCRTR2, CRHR1 | ATM 4876/4885CASP1 2713/4885CTSL 2388/4885 |
| US-20240002397-A1 | 3-AMINO PYRROLIDINE AND PIPERIDINE MACROCYCLIC OREXIN RECEPTOR AGONISTS | HCRTR1, HCRTR2, OXTR | ATM 4637/4885CASP1 3270/4885CTSL 1675/4885 |
| US-12552767-B2 | 3-heteroaryl pyrrolidine and piperidine orexin receptor agonists | HCRTR2, HCRTR1, NPY1R | ATM 4739/4885CASP1 2143/4885CTSL 2474/4885 |
| US-20050272669-A1 | Pyrazole derivatives, medicinal composition containing the same, medicinal use thereof, and intermediate for production thereof | UGGT1, GCKR, SLC5A1 | ATM 3438/4885CASP1 1629/4885CTSL 3195/4885 |
| US-20240002359-A1 | 3-HETEROARYL PYRROLIDINE AND PIPERIDINE OREXIN RECEPTOR AGONISTS | HCRTR2, HCRTR1, OXTR | ATM 4847/4885CASP1 3926/4885CTSL 1892/4885 |
| US-12312332-B2 | Heteroaryl pyrrolidine and piperidine orexin receptor agonists | HCRTR2, HCRTR1, OXTR | ATM 4864/4885CASP1 4029/4885CTSL 1888/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.